Stuttering – Cannabis THC : CBD Ratios

Stuttering Research Dashboard

1

Primary Studies

0

Related Studies

1

Total Studies

Clinical Studies

0

Clinical Meta-analyses

0

Double-blind human trials

0

Clinical human trials

Pre-Clinical Studies

1

Meta-analyses/Reviews

0

Animal studies

0

Laboratory studies

What am I missing as a non-subscriber?

To see a full dashboard with study details and filtering, go to our DEMO page.

As a subscriber, you will be able to access dashboard insights including chemotype overviews and dosing summaries for medical conditions and organ system and receptor breakdowns for cannabinoid and terpene searches. Study lists present important guidance including dosing and chemotype information with the ability to drill down to the published material. And all outputs are fully filterable, to help find just the information you need. Stay up-to-date with the science of cannabis and the endocannabinoid system with CannaKeys.

CannaKeys has 1 studies associated with Stuttering.

Here is a small sampling of Stuttering studies by title:


Components of the Stuttering Research Dashboard

  • Dosing information available for Stuttering
  • Chemotype guidance for treating Stuttering with cannabis
  • Synopsis of cannabis research for Stuttering
  • Individual study details for Stuttering

Ready to become a subscriber? Go to our PRICING page.

Select New Condition

Search By Keyword

Filter Condition

Members can filter by the following criteria:

  • Study Type
  • Chemotype
  • Cannabinoids & Endocannabinoids
  • Terpenes
  • Receptors
  • Ligands
  • Study Result
  • Year of Publication

Overview - Stuttering

Description of Stuttering

Stuttering is a specific developmental disorder affecting speech and language capacity in the language learning child that is characterized by the lack of an age-appropriate fluency. Stuttering affects boys three times more often than female children. Many children outgrow there stutter. However, in some people the stutter can become a chronic adult disorder and it is estimated that approximately 1% of the world’s population has some form of a stutter. The condition is not associated with an inappropriate flow of thoughts nor a muscular or skeletal inability to move the muscles needed to form speech. And, while stress or anxiety can become a stutter trigger it is not considered its cause. Since stuttering often occurs in family clusters it is posited to have a potential hereditary or genetic component which may be compounded by the presence of potential co-factors such as perinatal trauma. The expression of symptoms or the lack thereof can vary greatly depending on the environment. For instance, some people loose their stutter when they sing, whisper, or talk to pets suggesting the presence of positive triggers that free the patient (albeit temporarily) from the speech impediment.

Disease Classification

Condition: Stuttering
Disease Family:
Organ System: Mental/Emotional System, Nervous System
ICD-10 Chapter: Mental, Behavioral and Neurodevelopmental disorders
ICD-10 Code: F80.81

Stuttering Symptoms:

Signs and symptoms typically express on a spectrum of severity and can include a lack of flow of speech marked by hesitations, pausing, silent blocks, repetitions (involuntary), tension (tremble in lips, fixed postures), excessive blinking, frustration, the stretching of some words shortening of others, unusual intonations, for example. Common co-morbid symptoms include comorbidities such as social anxieties, shame, poor self-esteem or self-image, guilt, anger, or depression for instance.

Also known as:

Speech dysfluency, speech disorder, stammering, disorders of speech and language

Drug Interactions

THC Interaction with Pharmaceutical Drugs

  • THC can enhance the effects of drugs that cause sedation and depress the central nervous system, such as benzodiazepines, barbiturates, and alcohol, for example. 
  • THC is metabolized by and an inhibitor of a number of enzymatic liver pathways referred to as cytochrome P450. There are more than 50 enzymes belonging to this enzyme family, a number of which are responsible for the breakdown of common drugs such as antidepressants (e.g. amitriptyline, doxepine, fluvoxamine), antipsychotics (haloperidol, clozapine, stelazine), or beta-blockers (propranolol, theophylline, warfarin).  Thus patients taking these classes of medication may find that THC increases the concentration and effects of these drugs as well as the duration of their effects.
  • Clinical observation suggests no likely interactions with other pharmaceuticals at a total daily dose of up to 20mg THC.

CBD Interaction with Pharmaceutical Drugs

  • CBD may alter action on metabolic enzymes (certain drug-transport mechanisms), and as such may alter interactions with other drugs, some of which may produce therapeutic or adverse effects. For instance, CBD interacts with the enzyme cytochrome P450 3A4 and cytochrome P450 2C19, increasing the bioavailability of anti-epileptic drugs such as clobazam (a benzodiazepine). This makes it possible to achieve the same results at significantly lower dosages, reducing treatment costs and risks of adverse effects. 
  • Groups of drugs affected include: anti-epileptic drugs, psychiatric drugs, and drugs affecting metabolic enzymes, for example.
  • Clinical observations suggest no likely interactions with other pharmaceuticals at a total daily dose of up to 100mg CBD

Dosing Considerations

THC Dosage Considerations

  • THC micro dose:  0.1 mg to 0.4 mg (0.001mg/kg to 0.005mg/kg)
  • THC low dose:  0.5 mg to 5 mg (0.006mg/kg to 0.06mg/kg)
  • THC medium dose:  6 mg to 20 mg (0.08mg/kg to 0.27mg/kg)
  • THC high dose:  21 mg to 50+ mg (0.28mg/kg to 0.67mg/kg)
Formula for converting a set dose into mg/kg considerations: mg ÷ kg = mg/kg
(sample conversion calculated on a person weighing 75kg)

CBD Dosage Considerations

  • CBD low dose:  0.4 mg to 19 mg (0.005mg/kg to 0.25mg/kg)
  • CBD medium dose: 20 mg to 99 mg (0.26mg/kg to 1.32mg/kg)
  • CBD high dose:  100 mg to 800+ mg (1.33mg/kg to 10.7mg/kg)
  • (upper limits tested ~1,500mg)
Formula for converting a set dose into mg/kg considerations: mg ÷ kg = mg/kg
(sample conversion calculated on a person weighing 75kg)
Top

Disclaimers: Information on this site is provided for informational purposes only and is not meant to substitute for the advice provided by your own physician or other medical professional. You should not use the information contained herein for diagnosing a health problem or disease. If using a product, you should read carefully all product packaging. If you have or suspect that you have a medical problem, promptly contact your health care provider.

Information on this site is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. For many of the conditions discussed, treatment with prescription or over-the-counter medication is also available. Consult your physician, nutritionally oriented health care practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications.